Shares of Sun Pharmaceutical Industries were trading mildly lower on Monday, slipping 0.42% to Rs 1,788.70 as of 11:08 AM, while fresh legal action by Danish drugmaker Novo Nordisk came into focus in the Indian market.
According to earlier court developments, Novo Nordisk has approached the Delhi High Court seeking to restrain Indian companies from manufacturing the GLP-1 drug semaglutide, a globally popular molecule used for diabetes and weight-management therapies.
This follows the company’s ongoing litigation against Dr Reddy’s Laboratories (DRL), in which the Delhi High Court, earlier this week, refused to grant an interim injunction. The court allowed DRL to continue manufacturing and exporting its semaglutide-based formulation while the case proceeds.
Novo Nordisk had argued that DRL and its distributors should be barred from using, manufacturing, selling, distributing or exporting semaglutide API or any product derived from it. The petition was first filed in May.
While the legal dispute primarily concerns DRL, investor sentiment across the pharma sector remained cautious, with market participants watching how the litigation may influence future domestic manufacturing of GLP-1 therapies—an emerging high-value category globally.
Sun Pharma’s stock moved within a narrow intraday range of Rs 1,783.20 to Rs 1,801.20, with the company holding a market capitalisation of Rs 4.29 trillion.
